PMID- 20491016
OWN - NLM
STAT- MEDLINE
DCOM- 20100820
LR  - 20181201
IS  - 0022-9032 (Print)
IS  - 0022-9032 (Linking)
VI  - 68
IP  - 5
DP  - 2010 May
TI  - Early abciximab use in ST-elevation myocardial infarction treated with primary 
      percutaneous coronary intervention improves long-term outcome. Data from 
      EUROTRANSFER Registry.
PG  - 539-43
AB  - BACKGROUND: Primary percutaneous coronary intervention (PCI) is the preferred 
      method of reperfusion in patients with ST elevation myocardial infarction 
      (STEMI). Abciximab is a well established adjunct to primary PCI. The proper 
      timing of abciximab administration in STEMI patients has been investigated in 
      randomised trials, registries and metanalysis, providing conflicting results. 
      METHODS: Consecutive data on STEMI patients, transferred for primary PCI in 
      hospital/ambulance STEMI networks between November 2005 and January 2007, from 15 
      PCI centres in seven European countries was gathered together for a one-year 
      long-term clinical observation (93% rate of completeness). RESULTS: Data from 
      1,650 patients was collected in the EUROTRANSFER Registry. Abciximab was 
      administered to 1,086 patients (66%), 727 patients received early (at least 30 
      minutes prior to first balloon inflation) abciximab (EA), and another 359 
      patients received late abciximab (LA). One year mortality was 5.8% in the EA 
      group vs 10.3% with LA (p = 0.007). Adjustment for propensity score methods for 
      EA administration did not change the results, still providing a favourable 
      outcome for the EA group (p = 0.004). It was also revealed that only a minority 
      of patients (36%) were treated within the 90-minute recommended time window from 
      first medical contact to PCI (and 60% for the 120-min time delay). CONCLUSIONS: 
      Patients transferred for primary PCI in STEMI hospital networks showed lower 
      rates of death in long-term one-year clinical follow-up when treatment with 
      abciximab was started early.
FAU - Siudak, Zbigniew
AU  - Siudak Z
AD  - Institute of Cardiology, Collegium Medicum, Jagiellonian University, Krakow, 
      Poland. zbigniew.siudak@gmail.com
FAU - Rakowski, Tomasz
AU  - Rakowski T
FAU - Dziewierz, Artur
AU  - Dziewierz A
FAU - Janzon, Magnus
AU  - Janzon M
FAU - Birkemeyer, Ralf
AU  - Birkemeyer R
FAU - Stefaniak, Justyna
AU  - Stefaniak J
FAU - Partyka, Lukasz
AU  - Partyka L
FAU - Zmudka, Krzysztof
AU  - Zmudka K
FAU - Dudek, Dariusz
AU  - Dudek D
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - X85G7936GV (Abciximab)
SB  - IM
CIN - Kardiol Pol. 2010 May;68(5):544-5. PMID: 20491017
MH  - Abciximab
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Angioplasty, Balloon, Coronary
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Combined Modality Therapy
MH  - Drug Administration Schedule
MH  - Electrocardiography
MH  - Europe/epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoglobulin Fab Fragments/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/mortality/*therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Registries/*statistics & numerical data
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2010/05/22 06:00
MHDA- 2010/08/21 06:00
CRDT- 2010/05/22 06:00
PHST- 2010/05/22 06:00 [entrez]
PHST- 2010/05/22 06:00 [pubmed]
PHST- 2010/08/21 06:00 [medline]
PST - ppublish
SO  - Kardiol Pol. 2010 May;68(5):539-43.